An edition of Brain-disabling treatments in psychiatry
(1997)
Brain-disabling treatments in psychiatry
drugs, electroshock, and the psychopharmaceutical complex
2nd ed.
by Peter Roger Breggin
- 2 Want to read
Share
×Close
This work doesn't have a description yet. Can you add one?
Check nearby libraries
Buy this book
Previews available in: English
Subjects
Adverse effects, Brain, Brain damage, Chronic Brain Damage, Complications, Drug Industry, Effect of drugs on, Electroconvulsive therapy, Etiology, Iatrogenic diseases, Legislation, Mental Disorders, Psychotropic drugs, Side effects, Therapy, United States, United States. Food and Drug Administration, Electroconvulsive Therapy, Psychotropic Drugs, Hirnschadigung, Hersenbeschadiging, Psychopharmakon, Psychische Storung, Elektrokrampftherapie, Psychofarmaca, Arzneimittelnebenwirkung, Medizinschaden, Komplikation, Iatrogene ziekten, Elektroshocktherapie, United states, food and drug administration, Mental illness, treatment, Pharmaceutical industry, Brain chemistry, Public health & preventive medicine, Physician & patient, Pathology, Substance use & abuse - medical aspects, Pharmacology, Psychiatry - general & miscellaneous, The executive branch - general & miscellaneous, Health policy, PsychPlaces
United States| Edition | Availability |
|---|---|
1
Brain-disabling treatments in psychiatry: drugs, electroshock, and the psychopharmaceutical complex
2008, Springer Pub.
in English
- 2nd ed.
082612934X 9780826129345
|
aaaa
|
2
Brain-disabling treatments in psychiatry: drugs, electroshock, and the role of the FDA
1997, Springer Pub. Co.
in English
0826194907 9780826194909
|
eeee
|
Book Details
Table of Contents
The brain-disabling, spellbinding effects of psychiatric drugs
Deactivation syndrome (chemical lobotomy) caused by neuroleptics
neuroleptic-induced anguish, including agitation, despair, and depression
Severe and potentially irreversible neurological syndromes (tardive dyskinesia and neuroleptic malignant syndrome) caused by neuroleptics
Neuroleptic-induced neurotoxicity, brain damage, persistent cognitive deficits, dementia, and psychosis
Recent developments in antidepressant label changes
Antidepressant-induced mental, behavioral, and cerebral abnormalities
Lithium and other drugs for bipolar disorder
Electroconvulsive therapy (ECT) for depression
From attention-deficit/hyperactivity disorder (ADHD) to bipolar disorder : diagnosing America's children
Stimulant-induced brain damage, brain dysfunction, and psychiatric adverse reactions
Antianxiety drugs, including behavioral abnormalities caused by Xanax and Halcion
The Food and Drug Administration (FDA) and the National Institute of Mental Health (NIMH) : drug company advocates
Drug company deceptions
How to more safely stop taking psychiatric drugs
Failed promises, last resorts, and psychotherapy.
Edition Notes
Includes bibliographical references (p. 463-526) and index.
Classifications
The Physical Object
Edition Identifiers
Work Identifiers
Community Reviews (0)
Lists
See All
| December 20, 2023 | Edited by ImportBot | import existing book |
| July 17, 2022 | Edited by ImportBot | import existing book |
| October 8, 2021 | Edited by ImportBot | import existing book |
| May 27, 2020 | Edited by ImportBot | import existing book |
| December 8, 2009 | Created by ImportBot | add works page |